While conventional imaging modalities such as computed tomography (CT) and bone scans are widely utilized as initial diagnostic tools, the broad adoption of advanced imaging techniques—particularly prostate-specific membrane antigen positron emission tomography (PSMA PET) and whole-body MRI—has markedly improved the sensitivity and specificity of detecting metastatic disease [25]. The gene discussed is FOLH1; the disease is metastatic neoplasm.